Kemp Dolliver
Stock Analyst at Brookline Capital
(0.53)
# 3,845
Out of 4,734 analysts
18
Total ratings
33.33%
Success rate
-18.71%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $6.16 | +175.97% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $0.06 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.68 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.83 | +27.21% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $3.34 | +977.84% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $2.23 | +1,308.07% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.36 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $91.47 | +9.33% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.70 | +3,252.74% | 2 | Oct 12, 2023 | |
| PROC Procaps Group | Downgrades: Hold | $4.5 | $1.71 | +163.16% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $2.46 | +916.26% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $15.90 | +17.92% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $1.12 | +614.29% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.22 | +363.11% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $6.16
Upside: +175.97%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.06
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.68
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.83
Upside: +27.21%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $3.34
Upside: +977.84%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $2.23
Upside: +1,308.07%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.36
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $91.47
Upside: +9.33%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.70
Upside: +3,252.74%
Procaps Group
Sep 6, 2023
Downgrades: Hold
Price Target: $4.5
Current: $1.71
Upside: +163.16%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.46
Upside: +916.26%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $15.90
Upside: +17.92%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $1.12
Upside: +614.29%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.22
Upside: +363.11%